20.500.12556/DiRROS-24722 Emerging therapies and new directions in the treatment of pulmonary arterial hypertension Pulmonary arterial hypertension (PAH) is a severe and progressive disease with limited survival prospects under currently available therapies. Since the 2022 edition of the European Society of Cardiology and European Respiratory Society guidelines on pulmonary hypertension, substantial clinical evidence has emerged, supporting a new treatment algorithm for PAH as presented at the 7th World Symposium on Pulmonary Hypertension 2024 and the following proceeding papers. Key updates include the introduction of sotatercept as a second-line therapy leading to a revised definition of maximal medical therapy now encompassing agents from four therapeutic groups (phosphodiesterase-5 inhibitors/soluble guanylate cyclase stimulators, endothelin receptor antagonists, prostacyclin pathway agents, and sotatercept), instead of three (phosphodiesterase-5 inhibitors/soluble guanylate cyclase stimulators, endothelin receptor antagonists, prostacyclin pathway agents). Other novelties include the elimination of a distinct pathway for patients with cardiopulmonary comorbidities in favor of an individualized approach, a reduction in the initial patient assessment risk categories from three to two, and a follow-up interval shortened from 3–6 months to 3–4 months post-treatment initiation. This review presents these advancements and emphasizes the need for their widespread implementation in clinical practice. At the end, we present new opportunities and challenges in the treatment of pulmonary arterial hypertension in eight Central and Eastern European countries. activin signaling inhibitors novel therapies risk assessment treatment strategy sotatercept zaviralec signalizacije aktivina nove terapije ocena tveganja strategija zdravljenja sotatercept true false true Angleški jezik Slovenski jezik Neznano 2025-12-15 13:44:10 2025-12-15 13:44:11 2025-12-16 03:44:30 0000-00-00 00:00:00 2025 0 0 Nasl z nasl. zaslona; Opis z dne 17. 11. 2025; str. 18-26 no. 1 Vol. 83 2025 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.1 1897-4279 10.33963/v.phj.104053 257395459 RAZ_Kopec_Grzegorz_2025.pdf RAZ_Kopec_Grzegorz_2025.pdf 1 28D77DF26A126C62951604D5A83753A0 495d9e60bd24b6913bda4845c3be47bedea6a8894ae27ac4179b5f4370192802 e6a9288e-d9b3-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=36932 https://journals.viamedica.pl/polish_heart_journal/article/view/104053 0 f685915d-d9b3-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=36933 Univerzitetni klinični center Ljubljana 0 0 0